Skip to main content
Erschienen in: Clinical Rheumatology 9/2022

25.05.2022 | Original Article

Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study

verfasst von: Mary N. Ezeanuna, David K. Prince, Swetha Ann Alexander, John S. Richards, Gail S. Kerr, Diana Jalal, Nisha Bansal, Jean W. Liew, Namrata Singh

Erschienen in: Clinical Rheumatology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD) as well as with an increased risk of chronic kidney disease (CKD), also a known cardiovascular risk factor. However, it is not known if RA is a predictor of adverse outcomes in patients with CKD. We hypothesized that among a cohort of patients with CKD, RA would be associated with an increased risk of mortality.

Materials and methods

We conducted a retrospective study of 3939 participants with CKD from the prospective Chronic Renal Insufficiency Cohort (CRIC) study. The primary outcome of interest was all-cause mortality. Secondary outcomes included CKD progression (defined as end-stage kidney disease or 50% decline in estimated glomerular filtration rate), cardiovascular endpoints, and composite of myocardial infarction, cerebrovascular accident, heart failure, or death. Multivariable Cox proportional hazards regression was utilized, adjusting for potential confounders including age, sex, race/ethnicity, body mass index, current smoker, and education.

Results

The study cohort included 83 participants with RA on a disease modifying anti-rheumatic drug (DMARD). In the adjusted analysis, CKD-RA status was significantly associated with an increased risk of death (adjusted HR, aHR, 1.73 (1.27, 2.35)) and composite outcome (aHR 1.65 (1.27–2.15)) even after adjusting for traditional risk factors. Similar statistically significant associations were observed between CKD-RA and other secondary outcomes except for CKD progression.

Conclusion

RA was associated with higher mortality among individuals with CKD but not progressive renal decline. Further studies evaluating the mechanisms behind this association are needed.
Key Points
Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD) as well as with an increased risk of chronic kidney disease (CKD), also a known cardiovascular risk factor. However, it is not known if RA is an independent predictor of adverse outcomes in patients with CKD
In this study, we observed that CKD patients with RA experience higher mortality as well as an increased risk of CVD compared to patients with CKD without comorbid RA
These data provide rationale for more aggressive monitoring for CVD in patients with CKD and RA. They also underscore the need for determining which interventions can help decrease the burden of mortality in these patients
Literatur
1.
Zurück zum Zitat Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524–1529CrossRef Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524–1529CrossRef
2.
Zurück zum Zitat Blum A, Adawi M (2019) Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18(7):679–690CrossRef Blum A, Adawi M (2019) Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18(7):679–690CrossRef
3.
Zurück zum Zitat Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 71(3):277–283CrossRef Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 71(3):277–283CrossRef
4.
Zurück zum Zitat Fragoulis GE, Panayotidis I, Nikiphorou E (2020) Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 18(5):431–446CrossRef Fragoulis GE, Panayotidis I, Nikiphorou E (2020) Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 18(5):431–446CrossRef
5.
Zurück zum Zitat Davis JM III, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2008) The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 58(9):2603–2611CrossRef Davis JM III, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2008) The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 58(9):2603–2611CrossRef
6.
Zurück zum Zitat Giles JT, Simon LS, Pope J, Paik JS, Grabner M, Quebe A, Kannowski CL, Salinas CA, Curtis JR (2021) Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis. Rheumatol Ther 8(3):1383–1391CrossRef Giles JT, Simon LS, Pope J, Paik JS, Grabner M, Quebe A, Kannowski CL, Salinas CA, Curtis JR (2021) Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis. Rheumatol Ther 8(3):1383–1391CrossRef
7.
Zurück zum Zitat Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL et al (2003) The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol 14(7 Suppl 2):S148-153CrossRef Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL et al (2003) The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol 14(7 Suppl 2):S148-153CrossRef
8.
Zurück zum Zitat Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J et al (2009) Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4(8):1302–1311CrossRef Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J et al (2009) Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4(8):1302–1311CrossRef
9.
Zurück zum Zitat Formica MK, McAlindon TE, Lash TL, Demissie S, Rosenberg L (2010) Validity of self-reported rheumatoid arthritis in a large cohort: results from the Black Women’s Health Study. Arthritis Care Res 62(2):235–241 Formica MK, McAlindon TE, Lash TL, Demissie S, Rosenberg L (2010) Validity of self-reported rheumatoid arthritis in a large cohort: results from the Black Women’s Health Study. Arthritis Care Res 62(2):235–241
10.
Zurück zum Zitat Bansal N, McCulloch CE, Lin F, Alper A, Anderson AH, Cuevas M, Go AS, Kallem R, Kusek JW, Lora CM et al (2017) Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC study (chronic renal insufficiency cohort). Hypertension 70(2):435–443CrossRef Bansal N, McCulloch CE, Lin F, Alper A, Anderson AH, Cuevas M, Go AS, Kallem R, Kusek JW, Lora CM et al (2017) Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC study (chronic renal insufficiency cohort). Hypertension 70(2):435–443CrossRef
11.
Zurück zum Zitat Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A et al (2016) Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 315(20):2200–2210CrossRef Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A et al (2016) Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 315(20):2200–2210CrossRef
12.
Zurück zum Zitat Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1307CrossRef Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1307CrossRef
13.
Zurück zum Zitat Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697CrossRef Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697CrossRef
14.
Zurück zum Zitat Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26(5 Suppl 51):S35-61PubMed Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26(5 Suppl 51):S35-61PubMed
15.
Zurück zum Zitat Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103(5):398–406CrossRef Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103(5):398–406CrossRef
16.
Zurück zum Zitat Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs: results from a real-world study. Arthritis Care Res (Hoboken) 72(2):176–183CrossRef Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs: results from a real-world study. Arthritis Care Res (Hoboken) 72(2):176–183CrossRef
17.
Zurück zum Zitat Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52(8):2293–2299CrossRef Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52(8):2293–2299CrossRef
18.
Zurück zum Zitat Blake GJ, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 89(9):763–771CrossRef Blake GJ, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 89(9):763–771CrossRef
19.
Zurück zum Zitat Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18):2165–2168CrossRef Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18):2165–2168CrossRef
20.
Zurück zum Zitat Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9):1194–1197CrossRef Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9):1194–1197CrossRef
21.
Zurück zum Zitat Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG (2010) Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 25(1):119–124CrossRef Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG (2010) Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 25(1):119–124CrossRef
22.
Zurück zum Zitat Ortega O, Rodriguez I, Gallar P, Carreño A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A (2002) Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17(6):1105–1109CrossRef Ortega O, Rodriguez I, Gallar P, Carreño A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A (2002) Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17(6):1105–1109CrossRef
23.
Zurück zum Zitat Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS (2002) Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62(6):2208–2215CrossRef Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS (2002) Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62(6):2208–2215CrossRef
24.
Zurück zum Zitat Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68(1):237–245CrossRef Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68(1):237–245CrossRef
25.
Zurück zum Zitat Cheng YJ, Cheng XY, Zhang YM, Wang F, Wang X, Meng LQ, Liu G, Cui Z, Zhao MH (2022) Effects ofhydroxychloroquine on proteinuria in membranous nephropathy. J Nephrol 35(4):1145–1157CrossRef Cheng YJ, Cheng XY, Zhang YM, Wang F, Wang X, Meng LQ, Liu G, Cui Z, Zhao MH (2022) Effects ofhydroxychloroquine on proteinuria in membranous nephropathy. J Nephrol 35(4):1145–1157CrossRef
26.
Zurück zum Zitat Rodrigues JC, Bargman JM (2018) Antimalarial drugs for the prevention of chronic kidney disease in patients with rheumatoid arthritis: the importance of controlling chronic inflammation? Clin J Am Soc Nephrol 13(5):679–680CrossRef Rodrigues JC, Bargman JM (2018) Antimalarial drugs for the prevention of chronic kidney disease in patients with rheumatoid arthritis: the importance of controlling chronic inflammation? Clin J Am Soc Nephrol 13(5):679–680CrossRef
27.
Zurück zum Zitat Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489CrossRef Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489CrossRef
28.
Zurück zum Zitat Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(1):72–75CrossRef Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(1):72–75CrossRef
29.
Zurück zum Zitat del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 66(2):264–272CrossRef del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 66(2):264–272CrossRef
30.
Zurück zum Zitat Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56(3):820–830CrossRef Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56(3):820–830CrossRef
31.
Zurück zum Zitat Movahedi M, Costello R, Lunt M, Pye SR, Sergeant JC, Dixon WG (2016) Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Eur J Epidemiol 31(10):1045–1055CrossRef Movahedi M, Costello R, Lunt M, Pye SR, Sergeant JC, Dixon WG (2016) Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Eur J Epidemiol 31(10):1045–1055CrossRef
32.
Zurück zum Zitat Mantel Ä, Holmqvist M, Andersson DC, Lund LH, Askling J (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69(10):1275–1285CrossRef Mantel Ä, Holmqvist M, Andersson DC, Lund LH, Askling J (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69(10):1275–1285CrossRef
33.
Zurück zum Zitat Aslam F, Bandeali SJ, Khan NA, Alam M (2013) Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res (Hoboken) 65(4):534–543CrossRef Aslam F, Bandeali SJ, Khan NA, Alam M (2013) Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res (Hoboken) 65(4):534–543CrossRef
34.
Zurück zum Zitat Fan F, Galvin A, Fang L, White DA, Moore XL, Sparrow M, Cicuttini F, Dart AM (2014) Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) 11(1):29CrossRef Fan F, Galvin A, Fang L, White DA, Moore XL, Sparrow M, Cicuttini F, Dart AM (2014) Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) 11(1):29CrossRef
35.
Zurück zum Zitat Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271CrossRef Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271CrossRef
36.
Zurück zum Zitat Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, Therneau TM, Gabriel SE (2011) The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 38(8):1601–1606CrossRef Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, Therneau TM, Gabriel SE (2011) The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 38(8):1601–1606CrossRef
37.
Zurück zum Zitat Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, Lin WC, Cheng YP, Tsai TF, Ho SY (2015) Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications - a national population-based cohort study. PLoS ONE 10(9):e0136508CrossRef Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, Lin WC, Cheng YP, Tsai TF, Ho SY (2015) Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications - a national population-based cohort study. PLoS ONE 10(9):e0136508CrossRef
38.
Zurück zum Zitat Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732CrossRef Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52(3):722–732CrossRef
Metadaten
Titel
Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study
verfasst von
Mary N. Ezeanuna
David K. Prince
Swetha Ann Alexander
John S. Richards
Gail S. Kerr
Diana Jalal
Nisha Bansal
Jean W. Liew
Namrata Singh
Publikationsdatum
25.05.2022
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 9/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06223-x

Weitere Artikel der Ausgabe 9/2022

Clinical Rheumatology 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.